Roche Holding : Feedback from EASD call
>Differentiated clinical profiles of CT-388 and CT-996 not validated at this stage - At last week's EASD, Roche presented new phase I clinical data for its two lead compounds in obesity, including the following:CT-388 (GIP/GLP-1; weekly injection): data at 24 weeks showed a weight reduction of 18.9% at the highest dose, making CT-388 one of the most potent products currently in development. For example, weight loss was 17.5% for Lilly's retatrutide at 24 weeks ...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.